title: Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents.
abstract: Toxicity and chemoresistance are two major issues to hamper the success of current standard tumor chemotherapy. Combined therapy of agents with different mechanisms of action is a feasible and effective means to minimize the side effects and avoid the resistance to chemotherapeutic drugs while improving the antitumor effects. As the most essential tumor suppressor, p53 or its pathway has been an attractive target to develop a new type of molecule-targeting anticancer therapy. Recently, we identified a small molecule, Inauhzin (INZ), which can specifically activate p53 by inducing its deacetylation. In this study, we tested if combination with INZ could sensitize tumor cells to the current chemotherapeutic drugs, cisplatin (CIS) and doxorubicin (DOX). We found that compared with any single treatment, combination of lower doses of INZ and CIS or DOX significantly promoted apoptosis and cell growth inhibition in human non-small lung cancer and colon cancer cell lines in a p53-dependent fashion. This cooperative effect between INZ and CIS on tumor suppression was also confirmed in a xenograft tumor model. Therefore, this study suggests that specifically targeting the p53 pathway could enhance the sensitivity of cancer cells to chemotherapeutic agents and markedly reduce the doses of the chemotherapy, possibly decreasing its adverse side effects.
authors: Department of Biochemistry and Molecular Biology and Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA.
authors: Yiwei
authors: Y
authors: Zhang
authors: Qi
authors: Q
authors: Zhang
authors: Shelya X
authors: SX
authors: Zeng
authors: Qian
authors: Q
authors: Hao
authors: Hua
authors: H
authors: Lu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D051379:Mice; D016513:Mice, SCID; D010640:Phenothiazines / Q000494:pharmacology*; D047368:Tumor Burden / Q000187:drug effects; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D010640:Phenothiazines; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; C573921:inauzhin; D004317:Doxorubicin; D002945:Cisplatin
references: Br J Pharmacol. 2007 Jul;151(6):771-8
references: 17519947
references: Int J Radiat Oncol Biol Phys. 2007;69(2 Suppl):S106-8
references: 17848273
references: Biochem Pharmacol. 2011 Dec 1;82(11):1630-40
references: 21903092
references: Mol Cancer Ther. 2006 May;5(5):1239-47
references: 16731756
references: Nature. 2000 Nov 23;408(6811):433-9
references: 11100718
references: J Cell Physiol. 2011 Sep;226(9):2415-28
references: 21660965
references: PLoS One. 2012;7(3):e33867
references: 22439007
references: Toxicology. 2008 Jul 30;249(2-3):184-93
references: 18583013
references: Oncogene. 2003 Oct 20;22(47):7265-79
references: 14576837
references: Eur J Cancer. 2003 Nov;39(17):2450-61
references: 14602131
references: Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
references: 18594563
references: Cell. 2002 Jan 25;108(2):153-64
references: 11832206
references: EMBO J. 2006 Mar 22;25(6):1207-18
references: 16511572
references: Cell Death Differ. 2008 May;15(5):841-8
references: 18219319
references: Nat Rev Cancer. 2009 Oct;9(10):749-58
references: 19776744
references: EMBO Mol Med. 2012 Apr;4(4):298-312
references: 22331558
references: Circulation. 2007 Jul 31;116(5):506-14
references: 17638931
references: J Thorac Cardiovasc Surg. 2008 May;135(5):1036-41
references: 18455581
references: J Cell Physiol. 2011 Dec;226(12):3433-41
references: 21344396
references: Biomaterials. 2012 Feb;33(5):1596-606
references: 22079777
references: Cancer. 1999 Oct 1;86(7):1307-13
references: 10506718
references: Cancer Res. 2003 Nov 1;63(21):7081-8
references: 14612499
references: PLoS One. 2011 Apr 21;6(4):e19198
references: 21532991
references: Biochem Biophys Res Commun. 2006 Aug 18;347(1):60-6
references: 16815295
references: J Clin Oncol. 2009 Jan 1;27(1):127-45
references: 19018081
references: J Biol Chem. 2009 Feb 6;284(6):3823-32
references: 19075016
references: Science. 2004 Feb 6;303(5659):844-8
references: 14704432
references: Cancer Cell. 2005 Jun;7(6):547-59
references: 15950904
references: EMBO J. 2005 Oct 5;24(19):3411-22
references: 16163388
references: Nat Med. 2004 Dec;10(12):1321-8
references: 15558054
references: Cancer Res. 2006 Mar 15;66(6):3126-36
references: 16540663
references: Int J Cancer. 2007 Feb 15;120(4):927-34
references: 17131338
references: Cell. 2005 Nov 4;123(3):437-48
references: 16269335
references: Annu Rev Pharmacol Toxicol. 2009;49:223-41
references: 18834305
references: Oncol Rep. 2005 Jun;13(6):1229-34
references: 15870947
references: Cancer Ther. 2003;1:47-61
references: 18185852
references: Cancer. 2008 Oct 1;113(7 Suppl):1857-87
references: 18798529
references: Cell. 1992 Jun 26;69(7):1237-45
references: 1535557
references: Cold Spring Harb Perspect Biol. 2010 Dec;2(12):a000893
references: 20463001
references: Hematol Oncol. 2007 Dec;25(4):198-203
references: 17654614
references: EMBO J. 2006 Mar 22;25(6):1196-206
references: 16511560
references: Anticancer Res. 2002 May-Jun;22(3):1649-53
references: 12168849
references: Oncogene. 2012 Apr 26;31(17):2175-86
references: 21927021
references: Nature. 2009 Oct 22;461(7267):1071-8
references: 19847258
references: Adv Enzyme Regul. 1984;22:27-55
references: 6382953
references: Oncogene. 2013 May 30;32(22):2756-66
references: 22797071
references: Mol Cell. 2010 Oct 22;40(2):205-15
references: 20965416
references: Proc Natl Acad Sci U S A. 2000 Nov 7;97(23):12547-52
references: 11070080
references: Oncogene. 2007 Dec 10;26(56):7773-9
references: 18066090
references: Cancer Cell. 2008 May;13(5):454-63
references: 18455128
references: Am J Pathol. 2001 Nov;159(5):1889-94
references: 11696449
references: Cancer Res. 2007 Jul 15;67(14):6612-8
references: 17638871
references: Nature. 1993 Apr 29;362(6423):857-60
references: 8479525
references: Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3933-8
references: 18316739
references: EMBO J. 2002 Nov 15;21(22):6236-45
references: 12426395
references: Hum Mutat. 2007 Jun;28(6):622-9
references: 17311302
references: Mol Carcinog. 2009 Jul;48(7):586-91
references: 19347880
references: Cancer. 2008 Aug 15;113(4):799-807
references: 18618574
references: Mol Cell. 2007 Dec 14;28(5):739-45
references: 18082599
references: N Engl J Med. 1998 Sep 24;339(13):900-5
references: 9744975
references: EMBO J. 2001 Mar 15;20(6):1331-40
references: 11250899
references: Cancer Lett. 2012 Dec 1;325(1):35-41
references: 22634494
references: Carcinogenesis. 1999 Apr;20(4):553-9
references: 10223181
references: J Biol Chem. 2012 Jun 15;287(25):20898-903
references: 22556425
references: Cancer Gene Ther. 2012 Mar;19(3):218-28
references: 22223137
references: Cell Cycle. 2007 Feb 15;6(4):414-7
references: 17312392
references: Trends Cell Biol. 2010 May;20(5):299-309
references: 20172729
references: Cancer Res. 2007 Jul 1;67(13):6026-30
references: 17616658
references: Mol Cancer Ther. 2008 Oct;7(10):3141-9
references: 18852117
references: Anticancer Res. 2010 Sep;30(9):3557-64
references: 20944137
references: Genes Dev. 1993 Jul;7(7A):1126-32
references: 8319905
references: Arch Immunol Ther Exp (Warsz). 2009 Nov-Dec;57(6):435-45
references: 19866340
references: Cancer Metastasis Rev. 2010 Dec;29(4):613-39
references: 20922462
references: Cell. 1997 Aug 22;90(4):595-606
references: 9288740
references: Biochem Pharmacol. 2010 Sep 15;80(6):827-37
references: 20653109
references: Radiother Oncol. 2001 Dec;61(3):309-12
references: 11731001
references: J Biol Chem. 1994 Jan 14;269(2):787-90
references: 8288625
references: Int J Cancer. 2008 Feb 1;122(3):534-46
references: 17918180
references: Science. 1991 Jul 5;253(5015):49-53
references: 1905840
references: J Biol Chem. 2010 Apr 2;285(14):10786-96
references: 20080970
references: J Biol Chem. 2002 Dec 27;277(52):50607-11
references: 12421820
references: Mol Carcinog. 2012 Jun;51(6):449-64
references: 21678497
references: Br J Cancer. 2004 Jun 14;90(12):2370-7
references: 15150572
references: Life Sci. 2005 Mar 4;76(16):1825-34
references: 15698860
references: Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1850-5
references: 21233423
references: Int J Gynecol Cancer. 2008 Mar-Apr;18(2):223-7
references: 17511800
references: Cancer. 1977 Apr;39(4):1362-71
references: 851939
references: Cancer Chemother Pharmacol. 2007 Feb;59(2):183-95
references: 16724239
references: Curr Top Med Chem. 2012;12(12):1376-90
references: 22794314
references: Curr Med Chem. 2001 Nov;8(13):1649-60
references: 11562284
references: Nature. 2000 Nov 16;408(6810):307-10
references: 11099028
references: Oncol Rep. 2003 Nov-Dec;10(6):1663-82
references: 14534679
references: Cancer Biol Ther. 2012 Aug;13(10):915-24
references: 22785205
references: Gynecol Oncol. 2005 Apr;97(1):26-34
references: 15790433
references: Pharmacol Toxicol. 2003 Sep;93(3):105-15
references: 12969434
references: N Engl J Med. 1991 Mar 21;324(12):808-15
references: 1997853
references: J Exp Clin Cancer Res. 2010 Jul 01;29:87
references: 20594324
references: Oncol Res. 1999;11(3):153-9
references: 10527075
references: Annu Rev Biochem. 2004;73:39-85
references: 15189136
references: Cell. 2009 May 15;137(4):609-22
references: 19450511